Literature DB >> 15135689

Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease.

Klaus Kölling1, Gjin Ndrepepa, Werner Koch, Siegmund Braun, Julinda Mehilli, Albert Schömig, Adnan Kastrati.   

Abstract

The question of whether mild hyperhomocysteinemia is a risk factor for coronary artery disease (CAD) has long been debated and is still unclear. We investigated whether there is a link between methylenetetrahydrofolate reductase (MTHFR) gene C677T and A1298C polymorphisms or plasma homocysteine and CAD. This is a case-control study that included 2,121 consecutive patients (cases) with angiographically proved CAD and 617 patients without CAD (controls). MTHFR gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B(12) concentrations were determined and coronary angiography was performed in all subjects. The distribution of MTHFR gene C677T genotypes in patients (or controls) was: CC-genotype in 915 cases, 43.1% (266 controls, 43.1%); CT-genotype in 955 cases, 45.0%, (283 controls, 45.9%); and TT-genotype in 251 cases, 11.9% (68 controls, 11.0%) (p = 0.84). The distribution of MTHFR gene A1298C genotypes in patients (or controls) was: AA-genotype in 973 cases, 45.9% (281 controls, 45.5%); AC-genotype in 905 cases, 42.7% (284 controls, 46.0%); and CC-genotype in 243 cases, 11.4% (52 controls, 8.5%) (p = 0.07). Patients with CAD had higher levels of plasma homocysteine (12.9 +/- 5.1 vs 11.9 +/- 4.5 micromol/L, p <0.001) and lower levels of folate (9.5 +/- 3.1 vs 9.9 +/- 3.8 ng/ml, p = 0.008) than controls. After adjustment for other risk factors for CAD, plasma homocysteine (p = 0.89), MTHFR gene C677T (p = 0.38), or A1298C polymorphisms (p = 0.13) were not independent correlates of CAD. This study demonstrated that MTHFR gene C677T or A1298C polymorphisms are not associated with the presence of angiographic CAD. Although there is an apparent association between elevated levels of homocysteine and CAD, this association is not independent of conventional cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135689     DOI: 10.1016/j.amjcard.2004.02.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).

Authors:  Maple M Fung; Rany M Salem; Michael S Lipkowitz; Vibha Bhatnagar; Braj Pandey; Nicholas J Schork; Daniel T O'Connor
Journal:  Nephrol Dial Transplant       Date:  2011-05-25       Impact factor: 5.992

2.  Genetic polymorphisms influence runners' responses to the dietary ingestion of antioxidant supplementation based on pequi oil (Caryocar brasiliense Camb.): a before-after study.

Authors:  Ana Luisa Miranda-Vilela; Graciana Souza Lordelo; Arthur Kenji Akimoto; Penha Cristina Zaidan Alves; Luiz Carlos da Silva Pereira; Maria de Nazaré Klautau-Guimarães; Cesar Koppe Grisolia
Journal:  Genes Nutr       Date:  2011-04-11       Impact factor: 5.523

Review 3.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

4.  Association of MTHFR C677T (rs1801133) and A1298C (rs1801131) Polymorphisms with Serum Homocysteine, Folate and Vitamin B12 in Patients with Young Coronary Artery Disease.

Authors:  Rajni R Shivkar; Gayatri C Gawade; Meghana K Padwal; Arundhati G Diwan; Sumiran A Mahajan; Charushila Y Kadam
Journal:  Indian J Clin Biochem       Date:  2021-05-18

5.  Homocysteine and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Tunisian patients with severe coronary artery disease.

Authors:  Lakhdar Ghazouani; Nesrine Abboud; Nabil Mtiraoui; Walid Zammiti; Faouzi Addad; Haitham Amin; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2008-01-19       Impact factor: 2.300

6.  Genetic polymorphisms involved in folate metabolism and concentrations of methylmalonic acid and folate on plasma homocysteine and risk of coronary artery disease.

Authors:  Patrícia Matos Biselli; Alexandre Rodrigues Guerzoni; Moacir Fernandes de Godoy; Marcos Nogueira Eberlin; Renato Haddad; Valdemir Melechco Carvalho; Hélio Vannucchi; Erika Cristina Pavarino-Bertelli; Eny Maria Goloni-Bertollo
Journal:  J Thromb Thrombolysis       Date:  2009-03-13       Impact factor: 2.300

7.  Polygenic association with total homocysteine in the post-folic acid fortification era: the CARDIA study.

Authors:  Michael Y Tsai; Catherine M Loria; Jing Cao; Yongin Kim; David S Siscovick; Pamela J Schreiner; Naomi Q Hanson
Journal:  Mol Genet Metab       Date:  2009-06-06       Impact factor: 4.797

Review 8.  The treatment of hyperhomocysteinemia.

Authors:  Bradley A Maron; Joseph Loscalzo
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

9.  Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?

Authors:  Bradley A Maron; Joseph Loscalzo
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.967

10.  Failure to confirm influence of methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease.

Authors:  Wiebke Hansen; Carsten Saft; Jürgen Andrich; Thomas Müller; Stefan Wieczorek; Jörg T Epplen; Larissa Arning
Journal:  J Negat Results Biomed       Date:  2005-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.